These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21302038)

  • 1. Plasma pharmacokinetics and tissue distribution of bufotalin in mice following single-bolus injection and constant-rate infusion of bufotalin solution.
    Yu CL; Hou HM
    Eur J Drug Metab Pharmacokinet; 2011 Jan; 35(3-4):115-21. PubMed ID: 21302038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tissue distribution of five bufadienolides from the Shexiang Baoxin Pill following oral administration to mice.
    Huang H; Yang Y; Lv C; Chang W; Peng C; Wang S; Ge G; Han L; Zhang W; Liu R
    J Ethnopharmacol; 2015 Feb; 161():175-85. PubMed ID: 25196822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding.
    Hedaya MA; Daoud SS
    Anticancer Res; 2001; 21(6A):4005-10. PubMed ID: 11911284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
    Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of caspases and apoptosis-inducing factor in bufotalin-induced apoptosis of Hep 3B cells.
    Su CL; Lin TY; Lin CN; Won SJ
    J Agric Food Chem; 2009 Jan; 57(1):55-61. PubMed ID: 19055367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.
    Zhang DM; Liu JS; Tang MK; Yiu A; Cao HH; Jiang L; Chan JY; Tian HY; Fung KP; Ye WC
    Eur J Pharmacol; 2012 Oct; 692(1-3):19-28. PubMed ID: 22841670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
    Li F; Weng Y; Wang L; He H; Yang J; Tang X
    Int J Pharm; 2010 Jun; 393(1-2):203-11. PubMed ID: 20385221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
    Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
    Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of eltanolone following bolus injection and constant rate infusion.
    Parivar K; Wessén A; Widman M; Nilsson A
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):535-49. PubMed ID: 9300349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I.
    Sharkey EM; O'Neill HB; Kavarana MJ; Wang H; Creighton DJ; Sentz DL; Eiseman JL
    Cancer Chemother Pharmacol; 2000; 46(2):156-66. PubMed ID: 10972486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent.
    Tatsuta N; Suzuki N; Mochizuki T; Koya K; Kawakami M; Shishido T; Motoji N; Kuroiwa H; Shigematsu A; Chen LB
    Cancer Chemother Pharmacol; 1999; 43(4):295-301. PubMed ID: 10071980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
    Cusack BJ; Young SP; Driskell J; Olson RD
    Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic delivery of the anticancer agent arenobufagin using polymeric nanomicelles.
    Yuan X; Xie Q; Su K; Li Z; Dong D; Wu B
    Int J Nanomedicine; 2017; 12():4981-4989. PubMed ID: 28761339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.
    Scott-Moncrieff JC; Chan TC; Samuels ML; Cook JR; Coppoc GL; DeNicola DB; Richardson RC
    Cancer Chemother Pharmacol; 1991; 29(1):13-8. PubMed ID: 1742843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
    Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
    Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.
    Cárcel-Trullols J; Torres-Molina F; Araico A; Saadeddin A; Peris JE
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):153-60. PubMed ID: 15114410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methyl-beta-cyclodextrin and doxorubicin pharmacokinetics and tissue concentrations following bolus injection of these drugs alone or together in the rabbit.
    Grosse PY; Bressolle F; Rouanet P; Joulia JM; Pinguet F
    Int J Pharm; 1999 Apr; 180(2):215-23. PubMed ID: 10370192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion.
    Garrelts JC; Wagner DJ
    Ann Pharmacother; 1999 Dec; 33(12):1258-61. PubMed ID: 10630824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.